Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Myositis Associated ILD
NCT05335278Terminated
- Sponsor
- McGill University Health Centre
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of nintedanib in interstitial lung disease (ILD), sponsored by McGill University Health Centre. Primary endpoints: Tolerability - completed doses at 24 weeks and Safety and adverse events at 24 weeks. Started Jun 2021; status: terminated.
02
Drugs
nintedanib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05335278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335278.